Enterprise Value
3.045B
Cash
2.108B
Avg Qtr Burn
-39.86M
Short % of Float
19.33%
Insider Ownership
1.86%
Institutional Own.
70.86%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Approved Quarterly sales | ||
Approved Quarterly sales | ||
CTX110 (CD19) Details CD19+ malignancies, B-cell malignancies, Cancer, Blood cancer | Phase 2 Data readout | |
CTX211 (formerly VCTX211) Details Type 1 diabetes | Phase 1/2 Data readout | |
Phase 1/2 Update | ||
Phase 1/2 Update | ||
CTX310 (ANGPTL3) Details Atherosclerotic cardiovascular disease | Phase 1 Data readout | |
VCTX210 Details Type 1 diabetes | Phase 1 Data readout | |
CTX320 Lp(a) Details Atherosclerotic cardiovascular disease | Phase 1 Data readout | |
CTX112 (CD19) Details CD19+ malignancies, Blood cancer, B-cell malignancies, Cancer | Phase 1 Data readout | |
CTX131 (CD70) Details Cancer, Solid tumor/s | Phase 1 Data readout | |
CTX130 (CD70) Details Blood cancer, Cancer, T-cell lymphoma | Phase 1 Update | |
CTX120 (BCMA) Details Multiple myeloma, Blood cancer, Cancer | Failed Discontinued |